M&A Values Continued To Decline During Q4 2024
Evaluate data show that the biopharma industry made $9.5bn of acquisitions during the fourth quarter, a third consecutive quarter of decline, although deal volume rose to 33 from Q3’s 29.
Evaluate data show that the biopharma industry made $9.5bn of acquisitions during the fourth quarter, a third consecutive quarter of decline, although deal volume rose to 33 from Q3’s 29.